Pharma major Piramal Enterprises on Thursday said Saridon, its pain relief tablet, has been exempted from the list of banned fixed dose combinations (FDCs) by the Supreme Court.
In September last year, the apex court had stayed the ban, allowing Piramal to continue manufacturing, distribution and sale of Saridon, the company said in a statement.
"The Supreme Court of India has ruled in favor of Saridon, a heritage brand from the healthcare product portfolio of Piramal Enterprises Ltd (PEL), exempting its formulation from the list of banned FDCs," it said.
Commenting on the Supreme Court ruling, Nandini Piramal, Executive Director, Piramal Enterprises, said: "We are pleased with the Supreme Court ruling. This exemption from the banned list of FDCs validates our intent to serve our customers with the highest levels of integrity."
The company will continue to expand its healthcare product portfolio with an aim to be amongst the top three over the-counter product companies in India by 2020, she added.
Last year, the government had banned 328 FDCs including Saridon, on the basis of safety issues and lack of therapeutic justification.
--IANS
rrb/vd
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
